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Aminoacyl tRNA synthetases are known for catalysis
of aminoacylation. Significantly, some mammalian
synthetases developed cytokine functions possibly
linked to disease-causing mutations in tRNA synthe-
tases. Not understood is how epitopes for cytokine
signaling were introduced into catalytic scaffolds
without disturbing aminoacylation. Here we investi-
gate human tyrosyl-tRNA synthetase, where a cata-
lytic-domain surface helix, next to the active site,
was recruited for interleukin-8-likecytokinesignaling.
Taking advantage of our high resolution structure,
the reciprocal impact of rational mutations designed
to disrupt aminoacylation or cytokine signaling was
investigated with multiple assays. The collective
analysis demonstrated a protective fine-structure
separation of aminoacylation from cytokine activities
within the conserved catalytic domain. As a conse-
quence, disease-causing mutations affecting cell
signaling can arise without disturbing aminoacyla-
tion. These results with TyrRS also predict the previ-
ously unknown binding conformation of interleukin-
8-like CXC cytokines.
INTRODUCTION
Aminoacyl-tRNA synthetases catalyze aminoacylation of trans-
fer RNA (tRNA), specifically pairing amino acids with their
cognate anticodons on tRNA, thereby establishing the rules of
the genetic code. These enzymes are thought to have arisen
during the transition from the ‘‘RNA world’’ and their long evolu-
tion led to myriad structural and functional adaptations. For
example, specific enzymes developed editing activities during
evolution to increase specificity and selectivity of aminoacyla-
tion. In addition, idiosyncratic adaptations led to the develop-
ment of expanded cellular activities that link aminoacylation
with the broad systems biology of higher eukaryotes (Antonellis
and Green, 2008; Lee et al., 2004; Martinis et al., 1999; Park
et al., 2005, 2008). It is these expanded functions that are
thought to explain why heritable mutations in genes for specificChemistry & Biology 16,synthetases are causally connected to diseases (Antonellis and
Green, 2008; Park et al., 2008). Examples include mutations in
glycyl-, tyrosyl-, and aspartyl-tRNA synthetases, where either
protein synthesis or the respective aminoacylation activity is
unimpaired by the disease-causing mutation (Antonellis et al.,
2006; Jordanova et al., 2006; Nangle et al., 2007; Scheper
et al., 2007; Seburn et al., 2006). Not understood is how
a tRNA synthetase structural scaffold was expropriated for
another activity and done so in a way that does not disrupt ami-
noacylation. To better understand this question, we investigated
human TyrRS as an example. We chose this synthetase because
of the availability of our high resolution structure and of at least
three assays that can monitor its cytokine activity.
Several examples of diversification of the functional repertoire
of tRNA synthetases abound in literature. Thus, the unique
fused glutamyl-prolyl-tRNA synthetase regulates translational
silencing of ceruloplasmin, a multifunctional oxidase involved
in inflammation responses in mammals (Sampath et al., 2004).
Glutaminyl-tRNA synthetase has an antiapoptotic role through
its inhibition of the apoptosis signal-regulating kinase 1 in a gluta-
mine-dependent manner (Ko et al., 2001). Motif 1 of human lysyl-
tRNA synthetase interacts with the C-terminal capsid region of
the human immunodeficiency virus (HIV) gag protein and
promotes packaging of the HIV virion together with its tRNALys
primer for reverse transcription (Javanbakht et al., 2003). His-
tidyl-tRNA synthetase and asparaginyl-tRNA synthetase acti-
vate chemokine receptors on T lymphocytes and immature
dendritic cells (Howard et al., 2002). And a potent inhibitor of
angiogenesis is found in human tryptophanyl-tRNA synthetase,
whose expression is regulated by interferon-g (Wakasugi et al.,
2002a).
TyrRS developed cell signaling activities that are regulated by
its appended C-terminal domain (C-domain) (Figure 1A). Native,
full-length TyrRS has no known cytokine activity. Proteolytic
removal of the C-domain from TyrRS activates its cytokine func-
tion (Wakasugi and Schimmel, 1999a, 1999b). The N-terminal
fragment, mini-TyrRS, specifically stimulates migration of endo-
thelial cells and polymorphonuclear leukocytes (PMNs) and is
proangiogenic in cell-based assays (Wakasugi and Schimmel,
1999a; Wakasugi et al., 2002b) and in an ischemic mouse ear
angiogenesis model (Cheng et al., 2008). Mini-TyrRS is exported
from endothelial cells after treatment with tumor necrosis factor-
a and activates an array of angiogenesis signal transduction
pathways (Greenberg et al., 2008). The C-domain of TyrRS is531–539, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 531
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Dissecting Activities of Tyrosyl-tRNA Synthetaseunique to segmented animals, is distinct from the C-terminal
extension in bacterial TyrRSs, and is absent from yeast and
lower animals (like Caenorhabditis elegans) (Liu et al., 2002)
(Figure 1A). The C-domain itself also has cytokine activity. It is
a structural and functional homolog to another cytokine known
as endothelial monocyte activating polypeptide II (EMAPII) (Klee-
man et al., 1997; Liu et al., 2002). Both EMAPII and the C-domain
of TyrRS cause migration of mononuclear phagocytes and
PMNs, production of tumor necrosis factor-a and tissue factor
A
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Figure 1. Domains and Critical Motifs in TyrRS
(A) Schematic alignment comparing human full-length TyrRS with Saccharo-
myces cerevisiae and E. coli TyrRS. All TyrRSs have a catalytic Rossmann
fold catalytic domain (yellow) and an anticodon recognition domain (green).
Human TyrRS has an extra domain (C-domain; shown in blue) appended to
the C-terminal end of the anticodon recognition domain, which is not present
in yeast or E. coli TyrRS. (E. coli TyrRS has a smaller C-terminal extension
[purple] that is distinct from human TyrRS C-domain.) The ELR motif required
for cytokine activity of mini-TyrRS is indicated in red. This motif is absent in
yeast and E. coli TyrRS. Numbers in the schematic refer to amino acid
residues.
(B) Structure of mini-TyrRS (PDB 1q11) indicating the location of various
motifs. Removal of C-domain (not shown) from full-length TyrRS unmasks
the critical ELR motif essential for its cytokine activity. The first two domains
of full-length TyrRS (Rossmann fold catalytic domain in yellow and anticodon
recognition domain in green) constitute mini-TyrRS. HVAY and KMSSS (shown
as dotted lines as it is disordered in the crystal structure) motifs contribute to
the formation of ATP binding site and are essential for mini-TyrRS aminoacy-
lation activity. Tyr39 and Asp173 are required for tyrosine binding based on
interactions with the bound tyrosinol in the crystal structure. ELR motif (red)
is present on a surface helix (a5) and is critical for cytokine activity of mini-
TyrRS. Inset shows interactions around the ELRmotif. Arg93 side chainmakes
two hydrogen bonds with the main chain carboxyl oxygen of Ala340. The
aromatic ring of Tyr341 stacks with guanidino side chain of Arg93 and its
side chain hydroxyl makes a hydrogen bond with the main chain carboxyl
oxygen of Gly46 present in a loop before the HVAY tetrapeptide. Both the
main figure and inset was generated using PyMOL (DeLano, 2002).532 Chemistry & Biology 16, 531–539, May 29, 2009 ª2009 Elsevierby mononuclear phagocytes, and release of myeloperoxidase
from PMNs.
High resolution crystal structures of mini-TyrRS and of
C-domain enabled reconstruction of the structure of the full-
length enzyme that, in turn, provided the structural basis for
cytokine activation (Yang et al., 2002, 2003a, 2004). This activa-
tion is postulated to be achieved by exposing a three amino acid
motif (ELR) in the Rossmann fold catalytic domain, after proteo-
lytic removal of the C-domain. An ELR motif is critical for the
proangiogenic activities of chemokines such as interleukin-8
(IL-8) (Baggiolini and Clark-Lewis, 1992). The importance of the
ELR motif for cytokine activity of TyrRS was demonstrated by
an experiment in which placement of ELR motif into (cytokine-
inactive) yeast TyrRS led to gain of cytokine function (Liu et al.,
2002). To support the hypothesis for cytokine activation, a ratio-
nally designed mutation (Y341A) to open up the conformation of
TyrRS and expose the ELR motif without proteolytic cleavage
was constructed. Significantly, Y341A TyrRS had the same cyto-
kine activity as seen for mini-TyrRS (Yang et al., 2007b), strongly
supporting the importance of the ELR motif for cytokine activity.
Because the aminoacylation activities of TyrRS and mini-
TyrRS are the same, it is the core enzyme (mini-TyrRS) that
provides a direct connection of aminoacylation and cell
signaling. TyrRSs of lower eukaryotes lack the C-domain of the
mammalian enzymes and are closely similar to the mini-TyrRS
core enzyme, but appear not to have any cytokine activity.
Thus, over evolution, the mammalian enzymes acquired the
C-domain and adapted the mini-TyrRS core (by addition of
ELR motif) for cytokine signaling that is not seen in the lower
forms. While yeast TyrRS gained cytokine activity when the
ELR motif was transplanted (Liu et al., 2002), introduction of
the ELR motif also stimulated aminoacylation activity, suggest-
ing a potential correlation between the two activities. To under-
stand how cytokine signaling could be introduced without loss
of aminoacylation, we used our high resolution structure to guide
construction of variants that were investigated in a battery of
assays. These variants were specifically designed to disrupt
aminoacylation or cytokine signaling and seeing whether there
was ‘‘crosstalk’’ between these activities or whether they, in
the context of the variants, were insulated from each other.
RESULTS
Creating Catalytic Variants and Investigating
their Cytokine Function
Mini-TyrRS Variant with Disrupted Catalytic Activity
The aminoacylation reaction catalyzed by TyrRS occurs in two
steps. In the first step, tyrosine is activated through condensa-
tion with ATP to generate Tyr-AMP (tyrosyl adenylate), with the
release of pyrophosphate (PPi). In the second step, the activated
amino acid (Tyr-AMP) is covalently appended to the 30- end of
tRNATyr to give Tyr-tRNATyr and AMP. These activities come
from two distinct structurally segregated domains: a Rossmann
fold catalytic domain that is shared by all ten class I tRNA synthe-
tases and that houses the active site and the anticodon recogni-
tion domain (Figure 1B). An 11 amino acid signature sequence
peptide that ends in HIGH and a second peptide harboring
KMSKS contribute to formation of the ATP binding site (Arnez
and Moras, 1997; Webster et al., 1984). The signature peptidesLtd All rights reserved
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Figure 2. Mini-TyrRS Catalytic Variant Retains Cytokine Functions
(A) Mini-TyrRS(KMASA) catalytic variant has significantly reduced aminoacyla-
tion activity as compared with wild-type mini-TyrRS. In each case, enzyme
was tested for its ability to aminoacylate human tRNATyr with tyrosine. Mini-
TyrRS(KMASA) does not catalyze the first step of aminoacylation reaction
(formation of Tyr-AMP) as observed in a ATP-PPi exhange assay (inset).
(B) Mini-TyrRS catalytic variant is active in PMN cell migration assay. Each
protein or medium alone was added to the wells in the lower compartment
of a chemotaxis chamber, and freshly isolated human PMNs were placed in
the upper wells. The data show average number of cells per high power field
(HPF) migrating in response to culture medium, IL-8, mini-TyrRS, and mini-
TyrRS(KMASA) over a range of concentrations (0.1–100 nM). Medium indi-
cates background, whereas IL-8 is the positive control. Each condition was
performed in triplicate and mean ± SD is shown. The experiment was per-
formed three times and representative data from one experiment is shown
here.Chemistry & Biology 16can have degenerated sequences. In human TyrRS, the second
signature peptide has the specific sequence 222KMSSS226,
where S224 and S226 play an important role in catalyzing forma-
tion of Tyr-AMP (Austin and First, 2002a). Thus, S224A or S226A
reduced forward rate constant (for adenylate synthesis) by 7.5-
and 60- fold, respectively, without significantly affecting sub-
strate binding (Austin and First, 2002a).
We created S224A/S226A (KMSSS to KMASA) mini-TyrRS by
site-directed mutagenesis and tested its overall aminoacylation
activity by monitoring the incorporation of tyrosine into tRNATyr
to form Tyr-tRNATyr. Compared to wild-type mini-TyrRS, mini-
TyrRS(KMASA) has significantly reduced aminoacylation activity
(Figure 2A). To confirm that the catalytic deficiency resulted from
disruption of the first step of adenylate synthesis, as previously
suggested (Austin and First, 2002a), we measured tyrosine-
dependent ATP-PPi exchange, as an indication of synthesis of
Tyr-AMP. As anticipated, mini-TyrRS(KMASA) was defective in
this assay (Figure 2A, inset).
Aminoacylation-Defective Mini-TyrRS Variant Retains
Cytokine Activities
Next, the cytokine activities of mini-TyrRS(KMASA) were deter-
mined in two separate assays for cell signaling: PMNf cell migra-
tion and angiogenesis in the chick chorioallantoic membrane
(CAM) assay. Mini-TyrRS stimulates migration of PMN cells puri-
fied from human blood (Wakasugi and Schimmel, 1999a). Using
the same migration assay, we tested mini-TyrRS(KMASA), along
with wild-type mini-TyrRS and IL-8 as positive controls and
untreated cells as a negative control. Both wild-type and mini-
TyrRS(KMASA) had comparatively similar levels of stimulation
of migration of PMNs. They also showed the expected dose-
dependent bell-shaped chemotaxis activity that had maximum
migration at 10 nM (Figure 2B). This result suggested that the
catalytically defective variant was fully active for cytokine
signaling.
For further in vivo confirmation, we next carried out angiogen-
esis assays using CAMs to establish whether mini-TyrRS
(KMASA) retained its proangiogenic activity. In this in vivo
model, angiogenic factors stimulate new vessels to grow verti-
cally from the surface of the CAM membrane into a collagen
and nylon mesh implant. As a positive control, a well established
cytokine, the potent angiogenic vascular endothelial growth
factor (VEGF), was used to stimulate angiogenesis, while phos-
phate-buffered saline (PBS) was used as a negative control.
When compared to buffer alone, both mini-TyrRS and mini-
TyrRS(KMASA) stimulated new vessel growth into the collagen
matrix (Figure 2C).
(C) Mini-TyrRS catalytic variant is active in chick CAM angiogenesis
assay. Collagen was copolymerized with PBS, VEGF, mini-TyrRS, or mini-
TyrRS(KMASA) prior to placement of the collagen implant on the chick CAM.
The embryos containing the implants were incubated for a minimum of 66
hr. Blood vessels in representative implants were photographed in vivo
through a stereomicroscope. New vessels that grow up into the implants are
visualized within the grid boxes of the nylon mesh and scored as positive.
The preexisting, underlying CAM vessels are out of focus and are not scored
in the assay. The presence of VEGF, mini-TyrRS, or mini-TyrRS(KMASA)
clearly enhanced angiogenesis over the control implants (PBS treated). The
data represents average of the means from multiple experiments. For both
mini-TyrRS and mini-TyrRS(KMASA), the p-value was less than 0.005 as
compared to the control samples., 531–539, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 533
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genesis, disruption of aminoacylation, at the ATP binding site,
does not affect two cell signaling functions of mini-TyrRS.
Mini-TyrRS Variants with Disrupted Tyrosine Binding
Capacity
We next examined if the tyrosine binding capability of mini-
TyrRS contributed in any way to its cytokine activity. Based on
the crystal structure of mini-TyrRS, Tyr39 and Asp173 are
required for tyrosine binding (Yang et al., 2003b). Tyr39 is
conserved in eukaryotic, archaeal, and one of the two groups
of bacterial TyrRSs, while Asp173 is ubiquitously conserved
through evolution. A Y43G substitution in yeast TyrRS (corre-
sponds to Y39G in the human enzyme) increased the Km for tyro-
sine from 0.014 mM to 1.19 mM (Ohno et al., 2001). In order to
study the effect of abrogation of tyrosine binding capacity on
the cytokine function of TyrRS, we adopted a similar rational
mutagenesis approach in which we constructed single amino
acid variants (Y39A and D173A) and the combined Y39A/
D173A two amino acid variant. Recombinant wild-type mini-
TyrRS and its variants were purified from Escherichia coli.
Comparison of wild-type with its variants using circular
dichroism spectroscopy indicated that the proteins had similar
secondary structures (see Figure S1A available online). Impor-
tantly, all three variants had significantly reduced aminoacylation
activity (Figure 3A).
To confirm that the variants were defective in tyrosine binding,
we used an equilibrium dialysis binding assay to determine the
dissociation constants for tyrosine binding to wild-type mini-
TyrRS and its variants. In this assay, mini-TyrRS or its variants
were incubated with different concentrations of [3H]Tyr across
a semipermeable membrane. After the samples reached equilib-
rium, the amount of free tyrosine and tyrosine bound to the
protein was determined and used to calculate the dissociation
constant (KD), as explained in Experimental Procedures. The
KD for mini-TyrRS was 30 mM (Figure S2A). The Y39A/D173A
variant had greater than 25-fold reduction in tyrosine binding
with a KD of more than 700 mM (Figure S2B). This result showed
that, indeed, the Y39A/D173A mini-TyrRS has severely lost its
tyrosine binding capacity.
Tyrosine Binding Pocket Mini-TyrRS Variants Retain
Cytokine Activity
Cytokine activities of the tyrosine binding pocket variants ofmini-
TyrRS were studied by PMN cell and endothelial cell migration
assays. As described above, PMNs were freshly isolated from
humanblood. In these assays, IL-8was used as a positive control
and a mini-TyrRS(ELQ) variant (Arg93 to Gln) that lacks cytokine
activity (Wakasugi and Schimmel, 1999a) was used as a negative
control. The two single amino acid variants (Y39A and D173A)
and the double amino acid variant (Y39A/D173A) caused migra-
tion of cells similar to that observed for mini-TyrRS (Figure 3B).
Although the activitywas slightly less thanmini-TyrRS, it followed
the bell-shaped curve typical of such cytokines, consistent with
mini-TyrRS variants binding to their cognate cell surface receptor
and triggering downstream signaling events.
We next tested the activity of variants in an endothelial cell
migration assay. In these experiments, wounds of defined char-
acteristics were created in monolayers of human umbilical vein
endothelial cells (HUVECs). Mini-TyrRS or the tyrosine binding
pocket variants were added to the media to test for their ability534 Chemistry & Biology 16, 531–539, May 29, 2009 ª2009 Elsevierto close the wound by stimulating cell migration. Wound mono-
layers closed in response to VEGF within 6 hr (used as a positive
control) (Figure 3C). In cells treated with mini-TyrRS or its vari-
ants, a similar migration of cells into the wounded monolayer
was seen.
A
B
C
Figure 3. Mini-TyrRS Tyrosine Binding Pocket Variants Retain
Cytokine Functions
(A) Mini-TyrRS tyrosine binding pocket variants have significantly reduced
aminoacylation activity. [3H]Tyrosine incorporation into human tRNATyr by
10 nM TyrRS or its variants. The three variants (Y39A, D173A, and Y39A/
D173A) do not show any activity in the assay.
(B) Mini-TyrRS tyrosine binding pocket variants stimulate migration of PMN
cells comparable to that observed for mini-TyrRS. Protein samples (1–1000
nM) or medium alone was added to chemotaxis chamber in triplicate and
mean of number of cells migrated ± SD is shown.
(C) Tyrosine binding pocket variants are active in endothelial cell migration
assay. Mini-TyrRS and variants stimulated migration of HUVECs in a similar
manner. VEGF was used as a positive control. Migration of untreated mono-
layers was normalized to 1. Data from eight measurements was collected for
each sample and mean ± SD is shown.Ltd All rights reserved
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tion assays demonstrated that amino acid changes in the tyro-
sine binding pocket do not impact the cytokine activities of
mini-TyrRS. We further investigated the insulation of the tyrosine
binding pocket from cytokine function by performing the PMN
migration assay with mini-TyrRS under the influence of Tyr-SA
(50-O-[N-L-tyrosyl)sulfamoyl]adenosine; an analog of Tyr-AMP),
which is a potent inhibitor of aminoacylation and binding of
tyrosine. Tyr-SA did not inhibit the cytokine activity of mini-TyrRS
(Figure S3).
Cytokine Disruption Variants of the ELR Motif
on a Surface Helix and Effect on Aminoacylation
Mini-TyrRS Variants with Disrupted Cytokine Function
A surface helix (a5) on mini-TyrRS encodes an ELR motif
(Figure 1B) that functions like the ELR tripeptide in CXC cyto-
kines like IL-8. Having established that the cytokine activity of
mini-TyrRS is not affected by the aminoacylation activity per
se; we next addressed the converse—domutations that interfere
with cytokine activity also affect aminoacylation? Previously, we
demonstrated that substitution of Arg93 within the ELR motif (to
create mini-TyrRS(ELQ)) abolished the PMN cell migration
activity and the binding to PMN cells (Wakasugi and Schimmel,
1999a). Further, the ELQ variant did not induce endothelial cell
(HUVEC) migration in vitro and angiogenesis in vivo (Wakasugi
et al., 2002b).
To further dissect the ELR motif and the relationship, if any,
between the cytokine and aminoacylation activities, we changed
the first and the second residues of the ELR motif to their corre-
sponding residues in the cytokine-inactive yeast TyrRS, namely,
E91 to N (mini-TyrRS(NLR)) and L92 to Y (mini-TyrRS(EYR)). In
addition, we included the previously created R93 to Q variant
(mini-TyrRS(ELQ)) in the analyses. All variants were purified by
recombinant expression in E. coli and, based on circular
dichroism analysis, had secondary structure similar to that of
mini-TyrRS (Figure S1B).
The effect of replacing each of the ELR residues on the cyto-
kine activity of mini-TyrRS was evaluated by the PMN migration
and the endothelial cell wound healing assays. The effect of
these single amino acid changes on the PMN cell migration
activity of mini-TyrRS is shown in Figure 4A. As described above,
mini-TyrRS induced migration of PMN cells in a concentration-
dependent manner. However, mini-TyrRS(NLR) and mini-
TyrRS(ELQ) were inactive while mini-TyrRS(EYR) showed only
a minimal activity in the PMN cell migration assay. Thus, each
of the three ELR residues is important for cytokine function. As
expected, full-length TyrRS had no influence on migration.
To further test if position 92 would tolerate any change, we
also created and tested another variant L92 to E (mini-
TyrRS(EER)), based on the residue at the corresponding position
in the TyrRS sequence of the mosquito Anopheles gambiae.
Again, mini-TyrRS(EER) did not cause migration of PMN cells
(Figure S4), confirming the specificity and importance of L92
residue for the cytokine activity.
Figure 4B shows the results of an endothelial cell wound heal-
ing assay. As described above, in mini-TyrRS-treated samples,
closure of the wounded monolayer was observed. In contrast
to mini-TyrRS, all of the three single amino acid ELR variants
did not cause migration of endothelial cells. Although, migrationChemistry & Biology 16caused by mini-TyrRS(EYR) was slightly higher as compared to
the other two ELR variants, the activity itself was not statistically
significant as compared to the control. Mini-TyrRS(EYR) was
A
B
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Figure 4. Mini-TyrRS ELR Variants Lack Cytokine Activities
(A) Mini-TyrRS ELR variants do not stimulate migration of PMN cells. Protein
samples (1–1000 nM) or medium alone was run in triplicate and the mean of
number of cells migrated ± SD is shown. As control, IL-8 and mini-TyrRS
induced migration of PMN cells. Mini-TyrRS(NLR) and mini-TyrRS(ELQ) or
TyrRS did not stimulate migration of cells. Mini-TyrRS(EYR) had minimal cyto-
kine activity.
(B) Mini-TyrRS ELR variants do not stimulate migration of endothelial cells.
VEGF was used as a positive control. Migration of untreated monolayers
was normalized to 1. Data from eight measurements was collected for each
sample and mean ± SD is shown.
(C) Aminoacylation assays for mini-TyrRS and ELR variants. [3H]Tyrosine
incorporation into human tRNATyr, as catalyzed by 10 nM TyrRS or its variants.
Mini-TyrRS(EYR) variant showed activity comparable to wild-type mini-TyrRS.
Mini-TyrRS(NLR) had a slight decrease in activity. Mini-TyrRS(ELQ) had signif-
icantly reduced activity. Further, ATP-PPi exchange assay for mini-
TyrRS(ELQ) showed that it is defective in catalyzing the first step of the amino-
acylation reaction (inset)., 531–539, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 535
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et al., 2008). Overall, the three residues of the ELR motif are
important for mini-TyrRS cytokine activity. Similar result earlier
demonstrated the importance of mini-TyrRS ELR motif during
transactivation of VEGFR2 and endothelial cell tube formation
(Greenberg et al., 2008). As expected, full-length TyrRS did not
induce migration of cells.
Thus, these migration assays clearly demonstrated the re-
quirement of having an intact ELR motif for the cytokine activity
of mini-TyrRS.
Mini-TyrRS ELR Variants Retain Catalytic Activity
The next experiments determined how amino acid changes in
the ELRmotif (critical for cytokine activity) affect aminoacylation.
From the crystal structure of mini-TyrRS, the ELRmotif is located
on a long a helix (a5) on the surface of the Rossmann fold cata-
lytic domain (Figure 1B) (Yang et al., 2002). The three residues of
the ELRmotif form almost a full helical turn with the first two resi-
dues, E and L, being solvent exposed and available for interac-
tions with the cognate cellular receptor.
Replacement of E and L of the ELR motif abolished cytokine
activity, but had little effect on aminoacylation activity. Mini-
TyrRS(EYR) has wild-type-like aminoacylation activity. Mini-
TyrRS(NLR) has a small decrease in aminoacylation activity
(Figure 4C), possibly due to loss of H-bonding interactions of
E91 with surrounding residues that may have a slight effect of
stabilizing the active site. Nevertheless, the decrease in activity
is small, especially when the change in free energy is considered.
Thus, at the phenotypic level, these amino acid changes clearly
separate aminoacylation and cytokine activities, in the exact
reverse as was shown with the changes in the active site for
aminoacylation that did not perturb cytokine function.
R93-Dependent Positioning of the ELR-Containing Helix
Supports Simultaneous Retention of Cytokine
and Aminoacylation Activities
We figured that replacement of R93wasmore likely to affect ami-
noacylation as compared to the first two residues (EL) because
R93 structurally bridges the parts for aminoacylation with the
ELR motif (Yang et al., 2002). Particularly, R93 is in the center of
aH-bondingnetwork that stabilizes theconformationof theactive
site through interaction with the peptide harboring the HIGH
signature sequence (Figure 1B, inset). Thus, we speculated that
replacement of R93wouldmost likely disturb catalytic in addition
to cytokine activity. This speculation was confirmed with experi-
ments that showed that mini-TyrRS(ELQ) had significantly
reduced aminoacylation activity, consistent with a perturbation
of the H-bonding network that provides conformational stability
near the active site (Figure 4C). A follow-up ATP-PPi exchange
assay was performed on the ELQ variant to confirm that the
synthesis of Tyr-AMP was affected. Indeed, mini-TyrRS(ELQ)
had significantly reduced activity in this assay, showing that this
variant was defective for synthesis of Tyr-AMP (Figure 4C, inset).
Thus, R93 links the expanded cytokine function with aminoacyla-
tion and its substitution disrupts both activities of mini-TyrRS.
DISCUSSION
Little is known of how novel functions of tRNA synthetases were
developed in the context of their aminoacylation function. Simple536 Chemistry & Biology 16, 531–539, May 29, 2009 ª2009 Elsevierdomain fusions that bring in new functions appear to be
a straightforward way to bring in new activities without disturbing
aminoacylation. For example, in the case of the EMAPII-like
C-domain of TyrRS, two proteins (mini-TyrRS and C-domain)
were simply fused together in a way that did not disturb the
essential aminoacylation function of the mini-TyrRS part of
TyrRS. A similar situation occurs with the unusual glutamyl-prolyl
fusion synthetase, where the linker between the two synthetases
provides the determinants for regulation of translation of mRNAs
related to the inflammatory response (Jia et al., 2008; Ray and
Fox, 2007; Sampath et al., 2004). Thus, these examples show
that one strategy for a synthetase to gain an expanded function
is by acquisition of a new domain.
However, the potent cytokine activity of mini-TyrRS does not
come from a separate, fused domain. The activity arises from
within the core catalytic unit itself. In this instance, a long helix
that is part of the Rossmann fold of all class I tRNA synthetases
was exploited (Figure 1B). This helix is located on the surface
and not involved with forming a part of the active site. By having
a surface location, it is in principle accessible for interactionswith
a cellular receptor and, through evolution, could be exploited by
introducing sequence changes that facilitate receptor binding.
In this connection, earlier work suggested that selective pres-
sure to gain and retain an expanded function in a tRNA synthe-
tase would be strongest when a mutation that disrupted the
newly developing function also disrupted the essential aminoa-
cylation activity (Yang et al., 2007a). While substitutions of either
the E or L of the ELR motif (in the surface helix) of human TyrRS
ablated cytokine activities without having a major effect on ami-
noacylation, the R93Q substitution ablated both cytokine and
aminoacylation functions. Significantly, of the three amino acids
(ELR) only R93 is conserved for almost all eukaryotes. This
conservation may have been critical for the selective pressure
that enabled development of the cytokine function. Therefore,
while R was present in lower eukaryotes, the E and L combina-
tion only emerged in higher eukaryotes like mammals.
Thus, our results suggest that the development of the cytokine
function of TyrRS exploited two residues of a surface helix that
could be varied (positions 91 and 92 of the ELR tripeptide)
without disruption of aminoacylation. At the same time, an adja-
cent residue (R93) linked the developing cytokine activity to the
essential aminoacylation function. In addition to forcing retention
of R93, this strategy probably limited the possibilities for varia-
tions at positions 91 and 92, with only those that did not alter
the conformation of R93 and its role to stabilize the active site.
An ELR motif preceding the first cysteine at the N terminus is
a hallmark for CXC chemokines that are angiogenic, such as
IL-8. Each residue of the ELR motif in CXC chemokines is critical
for receptor binding and neutrophil activation (Hebert et al.,
1991). Here we showed that each of the same three residues is
also essential for the cytokine functions of mini-TyrRS. It is this
ELR motif that is believed to be essential for the ability of mini-
TyrRS to compete with IL-8 for the CXCR1 receptor (Wakasugi
and Schimmel, 1999a). Interestingly, the ELRmotif of mini-TyrRS
is encoded by a surface helix, but this motif in IL-8 is located in
a flexible region (Baldwin et al., 1991). Thus, we speculate that
the flexible N-terminal sequence of the ELR-containing CXC
chemokines adopts a helical conformation upon receptor
binding (Figure 5).Ltd All rights reserved
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causes of Charcot-Marie-Tooth disease (Jordanova et al.,
2006). While the cytokine activities of the proteins encoded by
the known mutant alleles have not been investigated, work is
underway to understand the link between cytokine activity and
the Charcot-Marie-Tooth disease phenotype. Regardless of
the outcome, the present investigation establishes the idea
that new motifs conferring novel activities can be added to
even a highly conserved part of the historical tRNA synthetase
architecture, with little effect on aminoacylation. Because of
this functional separation, potential disease-associated muta-
tions can affect only the cytokine function but not the essential
aminoacylation function and, therefore, in principle, can be
carried forward in the population.
SIGNIFICANCE
Heritable mutations in tRNA synthetases are causally linked
to disease. While aminoacyl-tRNA synthetases are universal
proteins known for catalysis of aminoacylation, the later
developed expanded functions of many mammalian
synthetases in cytokine signaling and regulatory pathways
are considered to be the main connection with diseases.
This work shows that the ancient conserved architecture
of tRNA synthetases can protect the essential aminoacyla-
tion function when new cell signaling epitopes are intro-
duced near the catalytic site. Consequently, because of
the protective isolation of the active site, disease-causing
mutations that affect only cell signaling can arise and be
transmitted.
Figure 5. Hypothesis that IL-8 N-Terminal Sequence Undergoes
Conformational Change upon Receptor Binding
ELR motif preceding the first cysteine at the N terminus is required for angio-
genic activity of CXC chemokines. In mini-TyrRS, this ELR is present on
a surface helix as compared to IL-8, in which it is part of a flexible loop.
Thus we hypothesize that this flexible N-terminal sequence of IL-8 adopts
a helical conformation upon receptor binding (shown by red circle). Conforma-
tion of unbound IL-8 was generated using PDB 1il8, and the receptor is shown
as a conceptual model. The other interacting region is shown by black dotted
circle. Disulfide bonds Cys7-Cys34 and Cys9-Cys50 are shown as yellow
solid lines.Chemistry & Biology 16EXPERIMENTAL PROCEDURES
Plasmids
Mutant human mini-TyrRS constructs were generated using QuikChange site-
directed mutagenesis kit (Stratagene) and using a plasmid encoding the gene
for wild-type human mini-TyrRS (Wakasugi and Schimmel, 1999a) as the
template for PCR mutagenesis reactions. Synthetic oligonucleotides were
purchased from Invitrogen. All proteins were expressed with a C-terminal
His-tag to facilitate purification.
Protein Purification and Removal of Endotoxin
Wild-type humanmini-TyrRS and its variants were purified as described previ-
ously (Wakasugi and Schimmel, 1999a). Recombinant proteins were overex-
pressed in E. coli strain BL21-CodonPlus (DE3)-RIL (Stratagene). Cultures
were grown in Luria Broth until log phase and then were induced with 1 mM
isopropyl b-D-thiogalactopyranoside (Novagen) for 4 hr. Cells were harvested
by centrifugation and lysed on ice by sonication in column buffer (20 mM Tris-
HCl [pH 7.9], 500mM sodium chloride, 30mM imidazole, and 5mM b-mercap-
toethanol), and the lysate was cleared by centrifugation at 35,000 g for 30 min.
The supernatant was loaded onto a Ni-NTA affinity column (QIAGEN) preequi-
librated with column buffer. The column was washed with column buffer con-
taining 0.1% Triton X-114 (Sigma) to dissociate lipopolysaccharide (endotoxin)
from the protein, followed by additional column buffer to remove residual
detergent. The protein was eluted with a gradient of 30–250 mM imidazole in
column buffer and stored in PBS (pH 7.4)/50% glycerol, 2 mM dithiothreitol,
and 1 mM zinc sulfate. All purified proteins were more than 95% pure as judged
by polyacrylamide gel electrophoresis (4%–12% Bis-Tris NuPAGE gels; Invi-
trogen). Protein concentration was determined using the Protein Assay
reagent (Bio-Rad) with bovine serum albumin (Sigma) as a standard. Endo-
toxin was removed using an EndoTrap Red column (Lonza) from samples
used for angiogenesis assays and endotoxin concentrations determined using
Kinetic-QCL Limulus Amebocyte Lysate assay (Lonza).
Amino Acid Activation Assay
Amino acid activation was assessed by monitoring the tyrosine-dependent
ATP-PPi exchange reaction (Calendar and Berg, 1966) at 37C. Each reaction
mixture contained 100 mM Tris-HCl (pH 7.8), 5 mM b-mercaptoethanol,
2 mM magnesium chloride, 1 mM ATP, 2 mM sodium pyrophosphate or
sodium [32P]-pyrophosphate (Perkin Elmer; specific activity: 37 TBq/mmol),
100 mg/ml bovine serum albumin, 2 mM tyrosine, and wild-type mini-TyrRS
or its variants. Aliquots were removed at various time points and quenched
into 200 mM sodium pyrophosphate, 11% perchloric acid, and 4% (w/v) acti-
vated charcoal. The reactionmixture was filtered through a 0.45 mmcentrifugal
filter (Fisher) and the charcoal was washed twice with a solution containing
200 mM sodium pyrophosphate and 1% perchloric acid. Charcoal-absorbed
[32P]ATP was quantified by scintillation counting.
Aminoacylation Assay
Aminoacylation activity was determined at ambient temperature in 150 mM
Tris-HCl (pH 7.5), 150 mM potassium chloride, 10 mM magnesium chloride,
10 mM b-mercaptoethanol, 4 mM ATP, and 10 mM tyrosine (including 3 mM
[3H]-tyrosine [GEHealthcare; specific activity: 3.7 TBq/mmol]). Human tRNATyr
was prepared as described earlier (Liu et al., 2002). Before each assay, 100 mM
human tRNATyr was annealed by heating at 65C for 5 min and cooled to room
temperature. Reactions were initiated by the addition of enzyme (10 nM) to the
reaction mixture. Aliquots were taken at fixed intervals and spotted ontoWhat-
man filter discs saturated with 5% trichloroacetic acid and dried. The filters
were placed into ice-cold 5% trichloroacetic acid and washed three times
with fresh 5% trichloroacetic acid at 4C and once with 95% ethanol. The level
of aminoacylation of tRNA was quantitated by liquid scintillation counting.
Equilibrium Binding Studies
Equilibrium dialysis was performed using a modification of the method
described earlier (Austin and First, 2002b). Prior to the binding experiment,
protein stocks were dialyzed in PBS (pH 7.4). The experiment was performed
by placing protein (20–40 mM) and tyrosine (3.6–1000 mM; [3H]-labeled; GE
Healthcare; specific activity: 3.7 TBq/mmol) suspended in PBS in the two
chambers on either side of a semipermeable membrane. After overnight, 531–539, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 537
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tillation counting and free and bound tyrosine calculated at each concentra-
tion. Dissociation constants were obtained by nonlinear and linear curve fitting
using the following two equations (Scatchard, 1949).
½Tyrbound=½ET = n½Tyrfree=
½Tyrfree +KTyr

½Tyrbound=½Tyrfree =
1=KTyr
½Tyrbound + n
½ET=KTyr

;
where KTyr is the dissociation constant for tyrosine, [Tyr]bound is the concentra-
tion of tyrosine bound to the enzyme, [Tyr]free is the concentration of unbound
tyrosine at equilibrium, n is the number of binding sites, and [E]T is the total
enzyme concentration.
PMN Migration Assay
Human PMNs were prepared from heparin treated whole blood from normal
healthy volunteers as described (Liu et al., 2002). Human PMNs were isolated
from blood by centrifugation (700 g) over Histopaque 1077 and 1119 as
described by the manufacturer (Sigma), washed three times with PBS, and
suspended in RPMI 1640 (American Type Culture Collection) containing
heat-inactivated fetal bovine serum (FBS) (0.5%; Invitrogen) at a concentration
of 4.0 3 105 cells/ml.
Cell migration was performed in a microchemotaxis chamber ChemoTX
(NeuroProbe) as described (Liu et al., 2002). Proteins, diluted in RPMI 1640,
were placed in the lower wells of the chamber separated by a polycarbonate
filter (5 mm pore) without polyvinylpyrrolidone (NeuroProbe) from 50 ml of the
PMN cell suspension in the upper chamber. Cells were allowed to migrate
for 30 min at 37C in a 5% CO2 incubator. After incubation, the membrane
was removed from the chemotaxis chamber and the nonmigrating cells care-
fully washed from the upper side of the membrane. The membrane was
stained with a Diff-Quik stain set (VWR International) and the cells migrated
to the lower side of the membrane were counted under a light microscope.
Samples were run in triplicate and cells counted in five high power fields for
each sample.
Endothelial Cell Migration Assay
Endothelial cell migration assays were performed as described earlier with
some modifications (Yang et al., 2007b). HUVECs (Lonza) were maintained
in endothelial growth media (Lonza) supplemented with 10% FBS in an atmo-
sphere of 5% CO2 in air at 37
C according to the supplier’s instructions. For
the migration assay, HUVECs were plated at a density of 3 3 105 cells/well
of a 6 well plate in endothelial growth media containing 10% FBS and grown
to confluent monolayers. Cells were starved in media containing no FBS for
16 hr and wounded across the well with a pipette tip. The wounded layers
were washed twice with serum-free media to remove cell debris and cells
were allowed to migrate with and without different mini-TyrRS proteins and
control factors. Images of the cell-free wound area were taken at 0 and 6 hr
and analyzed using image analysis software (NIH ImageJ 1.33). The wound
healing effect was calculated as the percentage of the remaining cell-free
area compared with the area of the initial wound and used to obtain the
percentage area closed for each condition.
CAM Angiogenesis Assay
Chicken embryo cultures were prepared as described by Seandel et al. (2001).
Fertilized COFAL-negative eggs (SPAFAS) were incubated horizontally at 37C
with 60% humidity in a manual egg-turning incubator (Lyon Electric Company,
Inc.). After 3.5 days, the shells were scored equatorially with a rotary wheel
(Dremel) and manually opened to transfer embryos into sterile plastic weigh
boats (medium, 9 3 9 3 2.5 cm; VWR). The weigh boats were covered with
square 100 3 100 mm petri dishes (Nunc) and embryos were maintained in
a cell culture incubator (NAPCO) at 37C with 90% humidity.
Angiogenic effects of mini-TyrRS and its variants were tested on CAMs as
described earlier (Seandel et al., 2001). Briefly, eight parts of pure type I
collagen (3.1 mg/ml) (Cohesion) was neutralized with one part 103 PBS and
one part 0.1 N sodium hydroxide. To maintain pH 7.4, HEPES (pH 7.4) was
added to a final concentration of 20 mM. Two parts neutralized collagen solu-
tion was combined with sterile PBS-containing bovine serum albumin (final
concentration of 1 mg/ml), with or without VEGF (PeproTech), mini-TyrRS, or538 Chemistry & Biology 16, 531–539, May 29, 2009 ª2009 Elseviermini-TyrRS variants. The final concentration of all protein samples was
1 mM. Collagen/protein solution (30 ml) was placed atop two layers of sterile
nylon mesh (Nitex; lower layer, 43 4 mm; upper layer, 23 2 mm) (Sefar Amer-
ican Inc.). These collagen/mesh implants were incubated at 37C with 90%
humidity for 1.5–2 hr to polymerize the collagen matrix. After polymerization,
the implants were placed on the CAM of a 10 day old chick embryo using
sterile forceps. Four implants were placed on each CAM, with at least one
negative control (PBS) and one positive control (VEGF) per embryo. The
embryos were returned to the incubator and observed on day 13 with a stereo-
microscope (Dolan-Jenner Industries). Distinct blood vessels appearing in the
collagen matrix at or above the plane of the top mesh were identified. Each
square in the topmesh grid was scored for the presence or absence of vessels
to give a proportion of positive boxes/total boxes counted.
SUPPLEMENTAL DATA
Supplemental Data include four figures and can be found with this article
online at http://www.cell.com/chemistry-biology/supplemental/S1074-5521
(09)00085-4.
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